IBCSG 46-13 LORELEI

  • A phase II randomized, double-blind study of neoadjuvant Letrozole Plus GDC-0032 versus Letrozole Plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer.

  • Study Chair
    Dr. Marco Colleoni, EIO, Milano Italy

    Statistician
    Christian Fesl, ABCSG, Vienna, Austria
    Ray Lin, Genentech, South San Francisco, CA, USA

    Study Manager:
    Christiaan McEwen, Sarah Brothers

    Trial Coordinator:
    Poonam Jani

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    August 5, 2014

    Targeted Accrual
    330

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login